Literature DB >> 16824733

Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2.

Marion Dorsch1, Anlai Wang, Hong Cheng, Chafen Lu, Andrew Bielecki, Kathryn Charron, Karl Clauser, Hong Ren, Roberto D Polakiewicz, Tom Parsons, Ping Li, Tim Ocain, Yajun Xu.   

Abstract

Receptor-interacting protein 2 (RIP2) is a serine-threonine kinase that mediates signaling for many receptors of the innate and adaptive immune systems. Toll like receptors (TLR) are an important component of the innate immune response. Stimulation of RIP2-deficient cells with ligands for TLR 2, 3 and 4 results in impaired cytokine production and decreased activation of NF-kB and MAP kinases compared to wild-type cells. Stimulation of TLR 4 with its ligand lipopolysaccaride (LPS) leads to the activation of RIP2 kinase activity and its autophosphorylation. Here we identify serine residue 176 as a site of autophosphorylation using a combination of mass spectrometry and mutational analysis. Mutation of S176 to alanine not only abolishes autophosphorylation of RIP2 but also significantly decreases its catalytic activity. A phospho-specific anti-S176 antibody detects wild-type RIP2 but not kinase-dead RIP2 or the RIP2 S176A mutant. Endogenous RIP2 in THP-1 cells and mouse bone marrow derived macrophages can be detected by the phospho-RIP2 (S176) antibody only after stimulation with LPS suggesting that the antibody recognizes activated RIP2. In summary, our results indicate that S176 is a regulatory autophosphorylation site for RIP2 and that S176 phosphorylation can be used to monitor the activation state of RIP2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824733     DOI: 10.1016/j.cellsig.2006.05.005

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  28 in total

1.  In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.

Authors:  Justine T Tigno-Aranjuez; Pascal Benderitter; Frederik Rombouts; Frederik Deroose; XiaoDong Bai; Benedetta Mattioli; Fabio Cominelli; Theresa T Pizarro; Jan Hoflack; Derek W Abbott
Journal:  J Biol Chem       Date:  2014-09-11       Impact factor: 5.157

2.  Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors:  Curt D Haffner; Adam K Charnley; Christopher J Aquino; Linda Casillas; Máire A Convery; Julie A Cox; Mark A Elban; Nicole C Goodwin; Peter J Gough; Pamela A Haile; Terry V Hughes; Beth Knapp-Reed; Constantine Kreatsoulas; Ami S Lakdawala; Huijie Li; Yiqian Lian; David Lipshutz; John F Mehlmann; Michael Ouellette; Joseph Romano; Lisa Shewchuk; Arthur Shu; Bartholomew J Votta; Huiqiang Zhou; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2019-10-11       Impact factor: 4.345

3.  Receptor-interacting protein 2 controls pulmonary host defense to Escherichia coli infection via the regulation of interleukin-17A.

Authors:  Theivanthiran Balamayooran; Sanjay Batra; Gayathriy Balamayooran; Shanshan Cai; Koichi S Kobayashi; Richard A Flavell; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2011-08-15       Impact factor: 3.441

Review 4.  Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease.

Authors:  Justine T Tigno-Aranjuez; Derek W Abbott
Journal:  Biochim Biophys Acta       Date:  2012-04-11

5.  A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.

Authors:  Ueli Nachbur; Che A Stafford; Aleksandra Bankovacki; Yifan Zhan; Lisa M Lindqvist; Berthe K Fiil; Yelena Khakham; Hyun-Ja Ko; Jarrod J Sandow; Hendrik Falk; Jessica K Holien; Diep Chau; Joanne Hildebrand; James E Vince; Phillip P Sharp; Andrew I Webb; Katherine A Jackman; Sabrina Mühlen; Catherine L Kennedy; Kym N Lowes; James M Murphy; Mads Gyrd-Hansen; Michael W Parker; Elizabeth L Hartland; Andrew M Lew; David C S Huang; Guillaume Lessene; John Silke
Journal:  Nat Commun       Date:  2015-03-17       Impact factor: 14.919

6.  The kinase activity of Rip2 determines its stability and consequently Nod1- and Nod2-mediated immune responses.

Authors:  Chiara Nembrini; Jan Kisielow; Abdijapar T Shamshiev; Luigi Tortola; Anthony J Coyle; Manfred Kopf; Benjamin J Marsland
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

7.  The role of RIP2 in p38 MAPK activation in the stressed heart.

Authors:  Sebastien Jacquet; Yasuhiro Nishino; Sarawut Kumphune; Pierre Sicard; James E Clark; Koichi S Kobayashi; Richard A Flavell; Jan Eickhoff; Matt Cotten; Michael S Marber
Journal:  J Biol Chem       Date:  2008-02-29       Impact factor: 5.157

8.  A regulatory region on RIPK2 is required for XIAP binding and NOD signaling activity.

Authors:  John Silke; Ueli Nachbur; Valentin J Heim; Laura F Dagley; Che A Stafford; Fynn M Hansen; Elise Clayer; Aleksandra Bankovacki; Andrew I Webb; Isabelle S Lucet
Journal:  EMBO Rep       Date:  2020-09-21       Impact factor: 8.807

9.  Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.

Authors:  Sameer Nikhar; Ioannis Siokas; Lisa Schlicher; Seungheon Lee; Mads Gyrd-Hansen; Alexei Degterev; Gregory D Cuny
Journal:  Eur J Med Chem       Date:  2021-02-03       Impact factor: 6.514

10.  Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide.

Authors:  Mark Windheim; Christine Lang; Mark Peggie; Lorna A Plater; Philip Cohen
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.